2025/03/18 更新

写真a

ババ タイスケ
馬場 泰輔
BABA Taisuke
所属
医学部附属病院 卒後臨床研修・キャリア形成支援センター 病院助教
職名
病院助教
外部リンク

学位 1

  1. 博士(医学) ( 2019年3月   名古屋大学 ) 

研究キーワード 8

  1. 胆道癌

  2. エピジェネティクス

  3. メタボロミクス

  4. AI

  5. バイオインフォマティクス

  6. 膵癌

  7. リキッドバイオプシー

  8. Precision medicine

研究分野 2

  1. ライフサイエンス / 消化器外科学  / 膵癌、胆道癌

  2. ライフサイエンス / 腫瘍生物学  / 膵癌, 胆道癌, バイオインフォマティクス, AI, メタボロミクス, エピジェネティクス

現在の研究課題とSDGs 3

  1. 胆管癌の早期診断を可能にする網羅的尿中メタボローム解析手法の開発

  2. 鶏卵漿尿膜(CAM)アバターで実現する希少がん個別化医療

  3. がん悪液質に伴う代謝異常に基づく早期膵癌・胆道癌診断AIの開発

経歴 3

  1. 名古屋大学   医学部附属病院 卒後臨床研修・キャリア形成支援センター   病院助教

    2023年10月 - 現在

  2. 名古屋大学   医学部附属病院 消化器外科一   病院助教

    2022年4月 - 2023年9月

  3. ハーバード医科大学 マサチューセッツ総合病院   外科   研究員

    2019年4月 - 2022年3月

      詳細を見る

    国名:アメリカ合衆国

学歴 2

  1. 名古屋大学   腫瘍外科

    2015年4月 - 2019年3月

      詳細を見る

    国名: 日本国

  2. 名古屋大学   医学部   医学科

    2001年4月 - 2007年3月

      詳細を見る

    国名: 日本国

所属学協会 5

  1. 日本メディカルAI学会

    2023年6月 - 現在

  2. 日本癌学会

    2023年4月 - 現在

  3. 日本肝胆膵外科学会

    2023年1月 - 現在

  4. 日本消化器外科学会

    2010年11月 - 現在

  5. 日本外科学会

    2009年6月 - 現在

受賞 2

  1. Travel grant

    2022年7月   国際膵臓学会  

     詳細を見る

    受賞区分:国際学会・会議・シンポジウム等の賞 

  2. 若手奨励賞

    2012年10月   東海外科学会  

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

 

論文 21

  1. Reappraisal of carcinoma in situ residue at the bile duct margin: a single-center review of 681 patients with perihilar cholangiocarcinoma

    Yamamoto R., Onoe S., Mizuno T., Watanabe N., Kawakatsu S., Sunagawa M., Yamaguchi J., Ogura A., Baba T., Igami T., Yamada M., Shimoyama Y., Ebata T.

    HPB   27 巻 ( 3 ) 頁: 362 - 370   2025年3月

     詳細を見る

    記述言語:英語   出版者・発行元:HPB  

    Background: A histologically involved surgical margin (R1) is often observed after resection for cholangiocarcinoma. Compared with a negative margin (R0), R1 with invasive carcinoma (R1inv) markedly worsens survival, whereas the prognostic effect of R1 with carcinoma in situ (R1cis) remains controversial. Methods: Patients who underwent resection for perihilar cholangiocarcinoma between 2002 and 2019 were retrospectively reviewed. According to the pathological assessment, the duct margin was classified as R0, R1cis, or R1inv; radial margin positivity was treated as R1inv. Recurrence and survival were compared. Results: Among the 681 patients, 457 had R0, 69 had R1cis, and 155 had R1inv. The overall five-year recurrence rate was 82.8 % with R1inv, 67.8 % with R1cis, and 47.6 % with R0 (P < 0.001); the local recurrence rate also significantly differed among these groups (P < 0.001). The five-year survival rate was significantly worse with R1cis than with R0 (37.3 % vs. 56.7 %, P < 0.001) and better than that with R1inv (20.9 %, P = 0.007). Multivariate analysis revealed that R1cis was an independent predictor of survival (hazard ratio, 1.65; P < 0.001). Conclusion: Compared with R0, R1cis significantly deteriorated overall survival in the whole resection subset of patients with perihilar cholangiocarcinoma. However, the prognostic impact of R1cis was milder than that of R1inv.

    DOI: 10.1016/j.hpb.2024.12.005

    Scopus

    PubMed

  2. Accumulating Genetic Mutations from Primary to Secondary Biliary Tract Cancers: Analysis of Four Patients With Metachronous Biliary Tract Cancer Using Comprehensive Genomic Profiling

    Kokuryo, T; Koike, Y; Yamaguchi, J; Sunagawa, M; Baba, T; Watanabe, N; Onoe, S; Mizuno, T; Ebata, T

    CANCER GENOMICS & PROTEOMICS   22 巻 ( 2 ) 頁: 346 - 353   2025年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.21873/cgp.20505

    Web of Science

    PubMed

  3. New Tumor Classification Using Invasion Depth in Biliary Tract Cancer Around the Cystic Duct Junction.

    Ushida Y, Watanabe N, Kawakatsu S, Yamamoto R, Mizuno T, Onoe S, Yokoyama Y, Kokuryo T, Igami T, Yamaguchi J, Sunagawa M, Baba T, Shimoyama Y, Ebata T

    Annals of surgery     2025年2月

     詳細を見る

    記述言語:英語  

    DOI: 10.1097/SLA.0000000000006672

    PubMed

  4. Negative Impact of High FOXP3 Status in Lymph Nodes of Esophageal Squamous Cell Carcinoma Patients

    Nonaka, Y; Baba, T; Sugita, S; Miyata, K; Sunagawa, M; Yamaguchi, J; Kokuryo, T; Yokoyama, Y; Ebata, T

    ANTICANCER RESEARCH   45 巻 ( 2 ) 頁: 781 - 787   2025年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background/Aim: Available data on the immune profiles of regional lymph nodes in individuals with esophageal squamous cell carcinoma (ESCC) are limited. This study investigated the immune profiles of proximal regional lymph nodes (PLNs) and evaluated the association between PLNs and the outcomes of patients with ESCC. Patients and Methods: This study included 39 patients with ESCC who underwent subtotal esophagectomy with three-field lymph node dissection. The immune profiles of tumor-infiltrating lymphocytes and PLNs were evaluated through immunohistochemistry. Furthermore, the impact of this immune profile on long-term outcomes was analyzed. Results: Cox proportional-hazards analysis for overall survival revealed that ypT ≥3 [hazard ratio (HR)=8.91; 95% confidence interval (CI)=1.59-49.8] and high FOXP3 status in PLNs (HR=4.29; 95%CI=1.06-17.4) are significant independent prognostic factors. Meanwhile, analysis of disease-free survival (DFS) revealed that ypT ≥3 (HR=5.52; 95%CI=1.15-26.6) and ypN ≥1 (HR=7.74; 95%CI=1.58-37.9) are independent prognostic factors. Furthermore, high FOXP3 status in PLNs was associated with low DFS rate, although the association was not statistically significant (HR=1.70; 95%CI=0.58-5.02). Conclusion: High FOXP3 status in PLNs is associated with poor prognosis in patients with ESCC.

    DOI: 10.21873/anticanres.17466

    Web of Science

    Scopus

    PubMed

  5. Whole-genome Sequencing Analysis of Bile Tract Cancer Reveals Mutation Characteristics and Potential Biomarkers Open Access

    Kokuryo, T; Sunagawa, M; Yamaguchi, J; Baba, T; Kawakatsu, S; Watanabe, N; Onoe, S; Mizuno, T; Ebata, T

    CANCER GENOMICS & PROTEOMICS   22 巻 ( 1 ) 頁: 34 - 40   2025年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Genomics and Proteomics  

    Background/Aim: Bile tract cancer (BTC) is a malignant tumor with a poor prognosis. Recent studies have reported the heterogeneity of the genomic background and gene alterations in BTC, but its genetic heterogeneity and molecular profiles remain poorly understood. Whole-genome sequencing may enable the identification of novel actionable gene mutations involved in BTC carcinogenesis, malignant progression, and treatment resistance. Patients and Methods: We performed whole-genome sequencing of six BTC samples to elucidate its genetic heterogeneity and identify novel actionable gene mutations. Somatic mutations, structural variations, copy number alterations, and their associations with clinical factors were analyzed. Results: The average number of somatic mutations detected in each case was 53,705, with SNVs accounting for most of these mutations (85.02%). None of the 331 mutations related to BTC in The Cancer Genome Atlas (TCGA) database were found in the mutations identified in our study. A higher prevalence of gene mutations was observed in samples without vascular invasion than in those with vascular invasion. Several genes with differences in mutation accumulation between groups were identified, including ADAMTS7, AHNAK2, and CAPN10. Conclusion: Our study provides novel insights into the genomic landscape of BTC and highlights the potential of whole-genome sequencing analysis to identify actionable gene mutations and understand the molecular mechanisms underlying this malignancy. The high mutational burden, structural variations, and copy number alterations observed in BTC samples in this study underscore the genetic complexity and heterogeneity of this disease.

    DOI: 10.21873/cgp.20484

    Open Access

    Web of Science

    Scopus

    PubMed

  6. Application of fluorescent cholangiography to complex biliary variants of the confluence of the cystic duct and the infraportal type of the left lateral bile duct during single-incision laparoscopic cholecystectomy: A case report Open Access

    Nishino, S; Igami, T; Yokoyama, Y; Mizuno, T; Yamaguchi, J; Onoe, S; Sunagawa, M; Watanabe, N; Baba, T; Kawakatsu, S; Ebata, T

    ASIAN JOURNAL OF ENDOSCOPIC SURGERY   18 巻 ( 1 ) 頁: e13404   2025年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Asian Journal of Endoscopic Surgery  

    A 21-year-old man was diagnosed with segmental adenomyomatosis of the gallbladder based on ultrasonography and computed tomography images. Computed tomography with drip infusion cholangiography revealed that the cystic duct joined the infraportal type of the left lateral bile duct (IPLLBD), which runs caudal to the umbilical portion, and that the left medial bile duct joined the right hepatic duct without forming the left hepatic duct. We planned a single-incision laparoscopic cholecystectomy with fluorescent cholangiography. The fluorescent cholangiography visualized the anatomic variant of the biliary system, and the cystic duct was divided safely. Fluorescent cholangiography is a suitable procedure to depict complex biliary anatomic variations in this patient. IPLLBD without the formation of the left hepatic duct is potentially hazardous during cholecystectomy.

    DOI: 10.1111/ases.13404

    Open Access

    Web of Science

    Scopus

    PubMed

  7. A clinical assessment of three-dimensional-printed liver model navigation for thrice or more repeated hepatectomy based on a conversation analysis Open Access

    Igami, T; Maehigashi, A; Nakamura, Y; Hayashi, Y; Oda, M; Yokoyama, Y; Mizuno, T; Yamaguchi, J; Onoe, S; Sunagawa, M; Watanabe, N; Baba, T; Kawakatsu, S; Mori, K; Miwa, K; Ebata, T

    SURGERY TODAY   54 巻 ( 10 ) 頁: 1238 - 1247   2024年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Surgery Today  

    Purposes: We performed a conversation analysis of the speech conducted among the surgical team during three-dimensional (3D)-printed liver model navigation for thrice or more repeated hepatectomy (TMRH). Methods: Seventeen patients underwent 3D-printed liver navigation surgery for TMRH. After transcription of the utterances recorded during surgery, the transcribed utterances were coded by the utterer, utterance object, utterance content, sensor, and surgical process during conversation. We then analyzed the utterances and clarified the association between the surgical process and conversation through the intraoperative reference of the 3D-printed liver. Results: In total, 130 conversations including 1648 segments were recorded. Utterance coding showed that the operator/assistant, 3D-printed liver/real liver, fact check (F)/plan check (Pc), visual check/tactile check, and confirmation of planned resection or preservation target (T)/confirmation of planned or ongoing resection line (L) accounted for 791/857, 885/763, 1148/500, 1208/440, and 1304/344 segments, respectively. The utterance’s proportions of assistants, F, F of T on 3D-printed liver, F of T on real liver, and Pc of L on 3D-printed liver were significantly higher during non-expert surgeries than during expert surgeries. Confirming the surgical process with both 3D-printed liver and real liver and performing planning using a 3D-printed liver facilitates the safe implementation of TMRH, regardless of the surgeon’s experience. Conclusions: The present study, using a unique conversation analysis, provided the first evidence for the clinical value of 3D-printed liver for TMRH for anatomical guidance of non-expert surgeons.

    DOI: 10.1007/s00595-024-02835-9

    Open Access

    Web of Science

    Scopus

    PubMed

  8. Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer Open Access

    Jinno, T; Yamaguchi, J; Ogura, A; Kokuryo, T; Yokoyama, Y; Sunagawa, M; Baba, T; Murata, Y; Ebata, T

    ANTICANCER RESEARCH   44 巻 ( 9 ) 頁: 3757 - 3769   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Anticancer Research  

    Background/Aim: Recent studies suggest that PD-L1 expression in immune cells, rather than tumor cells, plays a key role in tumor immunity. Trefoil factor family 1 (TFF1) is a secreted protein expressed mainly by the gastrointestinal epithelium and is related to the development of malignant disease. This study investigated the effects of TFF1 on tumor immunity in a xenograft mouse model of colorectal cancer (CRC). Materials and Methods: MC38 cells were implanted in wild-type (WT) and TFF1KO mice, and the tumor microenvironment was investigated using immunohistochemistry. The circulating immune cells were analyzed using flow cytometry. Results: Tumor growth was suppressed in TFF1KO mice. In the tumor microenvironment, CD8- and CD4-positive T cells and CD11c-positive dendritic cells (DCs) were frequently found in TFF1KO mice. When an immune checkpoint inhibitor was administered to these mice, almost half of the tumors in TFF1KO mice showed a complete response. The number of circulating PD-L1/DCs was markedly associated with tumor volume, with TFF1 deletion accelerating this effect and its injection decreasing it. These findings indicate that loss of TFF1 activates tumor immunity via frequent T-cell priming by DCs, and eventually suppresses tumor growth in CRC. In addition, the number of circulating PD-L1/DCs was identified as a predictive marker of checkpoint-inhibiting therapy efficacy. Conclusion: Loss of TFF1 resulted in accelerated immune response to colorectal cancer. Further studies are needed to investigate the precise mechanisms of TFF1 in immunotolerance and develop a novel TFF1-inhibiting immunotherapeutic strategy for CRC.

    DOI: 10.21873/anticanres.17200

    Open Access

    Web of Science

    Scopus

    PubMed

  9. Dysfunction of infiltrating cytotoxic CD8+T cells within the graft promotes murine kidney allotransplant tolerance Open Access

    Yokose, T; Szuter, ES; Rosales, I; Guinn, MT; Liss, AS; Baba, T; Ruddy, DA; Piquet, M; Azzi, J; Cosimi, AB; Russell, PS; Madsen, JC; Colvin, RB; Alessandrini, A

    JOURNAL OF CLINICAL INVESTIGATION   134 巻 ( 16 )   2024年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Clinical Investigation  

    Tolerance of mouse kidney allografts arises in grafts that develop regulatory tertiary lymphoid organs (rTLOs). Single-cell RNA-seq (scRNA-seq) data and adoptive transfer of alloreactive T cells after transplantation showed that cytotoxic CD8+ T cells are reprogrammed within the accepted graft to an exhausted/regulatory-like phenotype mediated by IFN-γ. Establishment of rTLOs was required because adoptive transfer of alloreactive T cells prior to transplantation results in kidney allograft rejection. Despite the presence of intragraft CD8+ cells with a regulatory phenotype, they were not essential for the induction and maintenance of kidney allograft tolerance since renal allotransplantation into CD8-KO recipients resulted in acceptance and not rejection. Analysis of scRNA-seq data from allograft kidneys and malignant tumors identified similar regulatory-like cell types within the T cell clusters and trajectory analysis showed that cytotoxic CD8+ T cells are reprogrammed into an exhausted/regulatory-like phenotype intratumorally. Induction of cytotoxic CD8+ T cell dysfunction of infiltrating cells appears to be a beneficial mechanistic pathway that protects the kidney allotransplant from rejection through a process we call “defensive tolerance.” This pathway has implications for our understanding of allotransplant tolerance and tumor resistance to host immunity.

    DOI: 10.1172/JCI179709

    Open Access

    Web of Science

    Scopus

    PubMed

  10. Liver remnant volume to body weight ratio of 0.65% as a lower limit in right hepatic trisectionectomy with bile duct resection

    Hayashi, D; Mizuno, T; Kawakatsu, S; Baba, T; Sando, M; Yamaguchi, J; Onoe, S; Watanabe, N; Sunagawa, M; Ebata, T

    SURGERY   175 巻 ( 2 ) 頁: 404 - 412   2024年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Surgery (United States)  

    Background: Previous studies have suggested the utility of an indocyanine green plasma clearance rate of the future liver remnant (FLR) (ICGK-F) ≥0.05 in hepatobiliary resection to reduce the surgical risk. The present study aimed to verify whether future liver remnant size rather than ICGK-F matters in extended hepatobiliary resection. Methods: Between 2004 and 2021, patients who underwent right hepatic trisectionectomy with bile duct resection were included. The effect of the FLR volume-to-body weight ratio (FLR/BW) and ICGK-F on posthepatectomy liver failure was evaluated along with other parameters. Results: Among 91 study patients, the median ICGK-F, FLR, and FLR/BW were 0.057 (range, 0.027–0.099), 392 mL (145–705), and 0.78% (0.40–1.37), respectively. Posthepatectomy liver failure occurred in 23 patients. The incidence was 10 (40%) in 25 patients with an ICGK-F <0.05 and 12 (18%) in 65 patients with an ICGK-F ≥0.05 (P = .053); 13 (52%) in 25 patients with a FLR/BW <0.65% and 10 (15%) in 66 patients with a FLR/BW ≥0.65% (P = .001). Multivariate analysis showed that a FLR/BW <0.65% (odds ratio, 11.7; P = .005), age ≥65 years (odds ratio, 31.7; P < .001), and blood loss ≥25 mL/kg (odds ratio, 22.1; P = .004) were independent predictors of posthepatectomy liver failure, but ICGK-F <0.05 was not (P = .499). According to the meeting number of 3 factors, posthepatectomy liver failure incidence was 0 of 22 (0%) in patients with 0 factors, 6 of 43 (14%) in patients with 1, and 17 of 26 (65%) in patients with 2 or 3 (P < .001). Conclusion: A FLR/BW ≥0.65% may serve as a volumetric basis to reduce posthepatectomy liver failure after extended hepatobiliary resection.

    DOI: 10.1016/j.surg.2023.09.037

    Web of Science

    Scopus

    PubMed

  11. The Goal of Intraoperative Blood Loss in Major Hepatobiliary Resection for Perihilar Cholangiocarcinoma Saving Patients From a Heavy Complication Burden 査読有り

    Kawakatsu, S; Mizuno, T; Yamaguchi, J; Watanabe, N; Onoe, S; Sunagawa, M; Baba, T; Igami, T; Yokoyama, Y; Imaizumi, T; Ebata, T

    ANNALS OF SURGERY   278 巻 ( 5 ) 頁: E1035 - E1040   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Annals of Surgery  

    Objective: To determine the goal of intraoperative blood loss in hepatectomy for perihilar cholangiocarcinoma. Background: Although massive bleeding can negatively affect the postoperative course, the target value of intraoperative bleeding to reduce its adverse impact is unknown. Methods: Patients who underwent major hepatectomy for perihilar cholangiocarcinoma between 2010 and 2019 were included. Intraoperative blood loss was adjusted for body weight [adjusted blood loss (aBL)], and the overall postoperative complications were evaluated by the comprehensive complication index (CCI). The impact of aBL on CCI was assessed by the restricted cubic spline regression. Results: A total of 425 patients were included. The median aBL was 17.8 (interquartile range, 11.8-26.3) mL/kg, and the CCI was 40.6 (33.7-49.5). Sixty-three (14.8%) patients had an aBL<10 mL/kg, nearly half (45.4%) of the patients were in the range of 10 ≤aBL<20 mL/kg, and 37 (8.7%) patients had an aBL >40 mL/kg. The spline regression analysis showed a nonlinear incremental association between aBL and CCI; CCI remained flat with an aBL under 10 mL/kg; increased significantly with an aBL ranging from 10 to 20 mL/kg; grew gradually with an aBL over 20 mL/kg. These inflection points of 10 and 20 mL/kg were almost consistent with the cutoff values identified by the recursive partitioning technique. After adjusting for other risk factors for the postoperative course, the spline regression identified a similar model. Conclusions: aBL had a nonlinear aggravating effect on CCI after hepatectomy for perihilar cholangiocarcinoma. The primary goal of aBL should be <10 mL/kg to minimize CCI.

    DOI: 10.1097/SLA.0000000000005869

    Web of Science

    Scopus

    PubMed

  12. 特集 肝門部胆管癌の治療戦略update II. 手術の実際 3.肝門部領域胆管癌の切除可能境界

    尾上 俊介, 水野 隆史, 渡辺 伸元, 川勝 章司, 横山 幸浩, 伊神 剛, 山口 淳平, 砂川 真輝, 馬場 泰輔, 江畑 智希

    外科   85 巻 ( 11 ) 頁: 1198 - 1202   2023年10月

     詳細を見る

    出版者・発行元:南江堂  

    DOI: 10.15106/j_geka85_1198

    CiNii Research

  13. "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience With 1290 Resections" 査読有り 国際共著 国際誌

    Roldán, J; Harrison, JM; Qadan, M; Bolm, L; Baba, T; Brugge, WR; Casey, BW; Krishnan, K; Mino-Kenudson, M; Pitman, MB; Kambadakone, A; Ferrone, CR; Warshaw, AL; Lillemoe, KD; Fernández-del Castillo, C

    ANNALS OF SURGERY   277 巻 ( 3 ) 頁: 491 - 497   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Annals of Surgery  

    Objective: The aim of this study was to describe our institutional experience with resected cystic tumors of the pancreas with emphasis on changes in clinical presentation and accuracy of preoperative diagnosis. Summary Background Data: Incidental discovery of pancreatic cystic lesions has increased and has led to a rise in pancreatic resections. It is important to analyze surgical outcomes from these procedures, and the prevalence of malignancy, pre-malignancy and resections for purely benign lesions, some of which may be unintended. Methods: Retrospective review of a prospective database spanning 3 decades. Presence of symptoms, incidental discovery, diagnostic studies, type of surgery, postoperative outcomes, and concordance between presumptive diagnosis and final histopathology were recorded. Results: A total of 1290 patients were identified, 62% female with mean age of 60 years. Fifty-seven percent of tumors were incidentally discovered. Ninety-day operative mortality was 0.9% and major morbidity 14.4%. There were 23 different diagnosis, but IPMN, MCN, and serous cystadenoma comprised 80% of cases. Concordance between preoperative and final histopathological diagnosis increased by decade from 45%, to 68%, and is presently 80%, rising in parallel with the use of endoscopic ultrasound, cytology, and molecular analysis. The addition of molecular analysis improved accuracy to 91%. Of misdiagnosed cases, half were purely benign and taken to surgery with the presumption of malignancy or premalignancy. The majority of these were serous cystadenomas. Conclusions: Indications and diagnostic work-up of cystic tumors of the pancreas have changed over time. Surgical resection can be performed with very low mortality and acceptable morbidity and diagnostic accuracy is presently 80%. About 10% of patients are still undergoing surgery for purely benign lesions that were presumed to be malignant or premalignant. Further refinements in diagnostic tests are required to improve accuracy.

    DOI: 10.1097/SLA.0000000000005142

    Web of Science

    Scopus

    PubMed

  14. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer 査読有り 国際誌 Open Access

    Kano, MT; Kokuryo, TOSHIO; Baba, TAISUKE; Yamazaki, KIMITOSHI; Yamaguchi, J; Sunagawa, M; Ogura, A; Watanabe, N; Onoe, S; Miyata, K; Mizuno, T; Uehara, K; Igami, T; Yokoyama, Y; Ebata, T; Nagino, M

    ANTICANCER RESEARCH   43 巻 ( 3 ) 頁: 1009 - 1016   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Anticancer Research  

    Background/Aim: α-Bisabolol is an essential oil component extracted from plants, such as chamomile. We have previously reported that α-bisabolol suppressed proliferation, invasion, and motility of pancreas cancer. Cyclodextrin improved the solubility of α-bisabolol, therefore it enabled to administer intravenously. The aim of this study was to clarify the effect of cyclodextrin conjugated α- bisabolol (CD-BSB) and the signals pathways associated with α-bisabolol for pancreatic cancer. Materials and Methods: Human pancreatic cancer cell lines were treated with or without CD-BSB. Cytomorphology and apoptosis were assessed in these treated groups. In addition, several phosphorylated proteins were analyzed to clarify the signal pathway concerning CD-BSB. In subcutaneous xenograft model, tumor volume and Ki-67 expression were evaluated among Control (untreated), CD-BSB, or Gemcitabine (GEM). Results: CD-BSB significantly changed cytomorphology and induced apoptosis in pancreatic cancer cells. CD-BSB suppressed phosphorylation of focal adhesion kinase (FAK). In addition, pFAK 397 was inhibited by CD-BSB in a concentration-dependent manner in cancer cells. In the subcutaneous xenograft models, the tumor volume in the CDBSB groups was lower than Control groups. Ki67-positive cells in CD-BSB treated group were lower than the GEMtreated groups. Conclusion: We clarified the efficiency of CDBSB in xenograft tumor using intravenous administration. α- Bisabolol suppresses phosphorylation of FAK 397 and impairs cytoskeletal polymerization in a pancreatic cancer cell line. Further investigations are required to reveal the precise mechanisms of the antitumor effects of solubilized α- bisabolol to facilitate its clinical application. Our data indicate that solubilized α-bisabolol has therapeutic potential and could improve the prognosis of cancer patients.

    DOI: 10.21873/anticanres.16245

    Open Access

    Web of Science

    Scopus

    PubMed

  15. 特集 血管再建を伴う高難度肝胆膵外科手術 6.肝門部領域胆管癌に対する肝動脈合併切除再建を伴う左側肝切除

    尾上 俊介, 水野 隆史, 渡辺 伸元, 川勝 章司, 横山 幸浩, 伊神 剛, 山口 淳平, 砂川 真輝, 馬場 泰輔, 江畑 智希

    外科   85 巻 ( 2 ) 頁: 145 - 154   2023年2月

     詳細を見る

    出版者・発行元:南江堂  

    DOI: 10.15106/j_geka85_145

    CiNii Research

  16. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines 査読有り 国際共著 国際誌 Open Access

    Baba, T; Finetti, P; Lillemoe, KD; Warshaw, AL; Fernández-Del Castillo, C; Liss, AS; Birnbaum, D; Bertucci, F

    GASTROENTEROLOGY   163 巻 ( 5 ) 頁: 1450 - +   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Gastroenterology  

    DOI: 10.1053/j.gastro.2022.07.005

    Web of Science

    Scopus

    PubMed

  17. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria

    Bolm, L; Pisuchpen, N; Qadan, M; Kambadakone, A; Sondermann, S; Mueller, K; Petruch, N; May, K; Zelga, P; Nebbia, M; Michelakos, T; Baba, T; Roldan, J; Harrison, JM; Honselmann, KC; Keck, T; Lillemoe, KD; Ferrone, CR; Wellner, UF; Fernandez-del Castillo, C

    ANNALS OF SURGERY   276 巻 ( 2 ) 頁: 215 - 221   2022年8月

     詳細を見る

    記述言語:英語   出版者・発行元:Annals of Surgery  

    Objective: Predicting R status before surgery for pancreatic cancer (PDAC) patients with upfront surgery and neoadjuvant therapy. Summary Background Data: Negative surgical margins (R0) are a key predictor of long-term outcomes in PDAC. Methods: Patients undergoing pancreatic resection with curative intent for PDAC were identified. Using the CT scans from the time of diagnosis, the 2019 NCCN borderline resectability criteria were compared to novel criteria: presence of any alteration of the superior mesenteric-portal vein (SMPV) and perivascular stranding of the superior mesenteric artery (SMA). Accuracy of predicting R status was evaluated for both criteria. Patient baseline characteristics, surgical, histopathological parameters, and long-term overall survival (OS) after resection were evaluated. Results: A total of 593 patients undergoing pancreatic resections for PDAC between 2010 and 2018 were identified. Three hundred and twenty-five (54.8%) patients underwent upfront surgery, whereas 268 (45.2%) received neoadjuvant therapy. In upfront resected patients, positive SMA stranding was associated with 56% margin positive resection rates, whereas positive SMA stranding and SMPV alterations together showed a margin positive resection rate of 75%. In contrast to these criteria, the 2019 NCCN borderline criteria failed to predict margin status. In patients undergoing neoadjuvant therapy, only perivascular SMA stranding remained a predictor of margin positive resection, leading to a rate of 33% R+ resections. Perivascular SMA stranding was related to higher clinical T stage (P = 0.003) and clinical N stage (P = 0.043) as well as perineural invasion (P = 0.022). SMA stranding was associated with worse survival in both patients undergoing upfront surgery (36 vs 22 months, P = 0.002) and neoadjuvant therapy (47 vs 34 months, P = 0.050). Conclusions: The novel criteria were accurate predictors of R status in PDAC patients undergoing upfront resection. After neoadjuvant treatment, likelihood of positive resection margins is approximately halved, and only perivascular SMA stranding remained a predictive factor.

    DOI: 10.1097/SLA.0000000000005433

    Web of Science

    Scopus

    PubMed

  18. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT). 査読有り 国際共著 国際誌

    Bolm L, Zemskov S, Zeller M, Baba T, Roldan J, Harrison JM, Petruch N, Sato H, Petrova E, Lapshyn H, Braun R, Honselmann KC, Hummel R, Dronov O, Kirichenko AV, Klinkhammer-Schalke M, Kleihues-van Tol K, Zeissig SR, Rades D, Keck T, Fernandez-Del Castillo C, Wellner UF, Wegner RE.

    Cancers   14 巻 ( 4 ) 頁: 868   2022年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/cancers14040868.

  19. ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN). 査読有り 国際共著 国際誌

    Zelga P, Hernández-Barco YG, Qadan M, Ferrone CR, Baba T, Bolm L, Jah A, Warshaw AL, Lillemoe KD, Balakrishnan A, Castillo CF.

    Pancreatology   22 巻 ( 2 ) 頁: 264 - 269   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.pan.2021.12.012.

  20. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. 査読有り 国際共著 国際誌

    Stefanie Lesch, Viktoria Blumenberg, Stefan Stoiber, Adrian Gottschlich, Justyna Ogonek, Bruno L. Cadilha, Zahra Dantes, Felicitas Rataj, Klara Dorman, Johannes Lutz, Clara H. Karches, Constanze Heise, Mathias Kurzay, Benjamin M. Larimer, Simon Grassmann, Moritz Rapp, Alessia Nottebrock, Stephan Kruger, Nicholas Tokarew, Philipp Metzger, Christine Hoerth, Mohamed-Reda Benmebarek, Dario Dhoqina, Ruth Grünmeier, Matthias Seifert, Arman Oener, Öykü Umut, Sandy Joaquina, Lene Vimeux, Thi Tran, Thomas Hank, Taisuke Baba, Duc Huynh, Remco T. A. Megens, Klaus-Peter Janssen, Martin Jastroch, Daniel Lamp, Svenja Ruehland, Mauro Di Pilato, Jasper N. Pruessmann, Moritz Thomas, Carsten Marr, Steffen Ormanns, Anna Reischer, Michael Hristov, Eric Tartour, Emmanuel Donnadieu, Simon Rothenfusser, Peter Duewell, Lars M. König, Max Schnurr, Marion Subklewe, Andrew S. Liss, Niels Halama, Maximilian Reichert, Thorsten R. Mempel, Stefan Endres & Sebastian Kobold

    Nature Biomedical Engineering   5 巻 ( 11 ) 頁: 1246 - 1260   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41551-021-00737-6.

  21. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer. 査読有り 国際誌

    Baba T, Kokuryo T, Yamaguchi J, Yokoyama Y, Uehara K, Ebata T, Nagino M.

    Anticancer Research   38 巻 ( 3 ) 頁: 1427 - 1434   2018年3月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.12367.

▼全件表示

MISC 1

  1. 胆道癌と代謝異常 招待有り

    馬場 泰輔、横山幸浩、國料俊男、伊神 剛、水野隆史、山口淳平、尾上俊介、砂川真輝、渡辺伸元、川勝章司、江畑智希  

    胆と膵44 巻 ( 5 ) 頁: 427 - 433   2023年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:日本語   掲載種別:記事・総説・解説・論説等(商業誌、新聞、ウェブメディア)  

講演・口頭発表等 8

  1. 膵癌Classicalサブタイプ研究とCAMモデル 招待有り

    馬場泰輔

    日本患者由来がんモデル学会学術集会2024  2024年8月22日  日本患者由来がんモデル学会

     詳細を見る

    開催年月日: 2024年8月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    開催地:東京   国名:日本国  

  2. Omicsデータをそのまま臨床検査に -AI時代の検査手法-

    馬場泰輔、砂川真輝、山口淳平、國料俊男、江畑智希

    第124回日本外科学会定期学術集会  2024年4月  日本外科学会

     詳細を見る

    開催年月日: 2024年4月

    記述言語:日本語   会議種別:ポスター発表  

    開催地:名古屋   国名:日本国  

  3. Inverse Pairs Boosting (IPB) technique for preclinical cancer detection: A novel approach with urine metabolomics

    Baba, T; Sunagawa, M; Yamaguchi, J; Mizuno, T; Kokuryo, T; Yokoyama, Y; Amano, H; Hinoki, A; Uchida, H; Ebata, T

    CANCER SCIENCE  2024年3月 

     詳細を見る

    開催年月日: 2024年3月

    記述言語:英語   会議種別:ポスター発表  

  4. A single sample classifier of Bailey's molecular subtype of PDAC. 国際会議

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Toshio Kokuryo, Tomoki Ebata

    AACR Special Conference: Pancreatic Cancer  2023年9月27日  American Association for Cancer Research

     詳細を見る

    開催年月日: 2023年9月

    記述言語:英語   会議種別:ポスター発表  

    開催地:Boston, US   国名:アメリカ合衆国  

  5. Inverse Pairs Boosting (IPB) technique for preclinical cancer detection - A novel approach with urine metabolomics

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Takashi Mizuno, Toshio Kokuryo, Yukihiro Yokoyama, Hizuru Amano, Akinari Hinoki, Hiroo Uchida, Tomoki Ebata

    第82回 日本癌学会 学術総会  2023年9月  日本癌学会

     詳細を見る

    開催年月日: 2023年9月

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:横浜   国名:日本国  

  6. Novel Urinary Biomarkers for Subclinical Detection of Early-Stage Cholangiocarcinoma. 国際会議

    Taisuke Baba, Masaki Sunagawa, Junpei Yamaguchi, Takashi Mizuno, Toshio Kokuryo, Hizuru Amano, Shun Kumano, Takashi Ishigaki, Akinari Hinoki, Tomoki Ebata

    第12回 日米癌合同会議  2022年12月  日本癌学会・米国癌学会

     詳細を見る

    開催年月日: 2022年12月

    記述言語:英語   会議種別:ポスター発表  

    開催地:Maui, US   国名:アメリカ合衆国  

  7. Remarkable plasticity of classical identity between pancreatic cancer cell lines and tumors. 国際共著 国際会議

    Taisuke Baba, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S Liss

    Joint Congress of the 26th Meeting of International Association of Pancreatology and the 53rd Annual Meeting of Japan Pancreas Society  2022年7月  IAP & JPS

     詳細を見る

    開催年月日: 2022年7月

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:京都   国名:日本国  

  8. A comparison between PDX tumors and PDX-derived cell lines highlights the molecular plasticity of pancreatic ductal adenocarcinoma. 国際共著 国際会議

    Taisuke Baba, Mari Mino-Kenudson, Keith D Lillemoe, Andrew L Warshaw, Carlos Fernández-Del Castillo, Andrew S Liss.

    American Pancreatic Association Annual Meeting   2021年11月  American Pancreatic Association

     詳細を見る

    開催年月日: 2021年11月

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:Miami, US   国名:アメリカ合衆国  

▼全件表示

共同研究・競争的資金等の研究課題 1

  1. 胆管癌の早期診断を可能にする網羅的尿中メタボローム解析手法の開発

    研究課題番号:A182  2023年4月 - 2024年3月

    国立研究開発法人日本医療研究開発機構 (AMED)  橋渡し研究プログラム シーズA 

    江畑智希、國料俊男、山口淳平、水野隆史、砂川真輝、伊藤喜介、檜 顕成

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4500000円 ( 直接経費:4368933円 、 間接経費:131067円 )

科研費 3

  1. 鶏卵漿尿膜(CAM)アバターで実現する希少がん個別化医療

    研究課題/研究課題番号:24K18048  2024年4月 - 2027年3月

    科学研究費助成事業  若手研究

    馬場 泰輔

      詳細を見る

    担当区分:研究代表者 

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    近年の悪性腫瘍に対する化学療法の進歩は目覚ましく、FOLFIRINOXなどの非常に強力なレジメンが導入され長期成績を伸ばしている。これらの化学療法の中には、軟部肉腫に対しても有効な薬剤が存在する可能性があるが、軟部肉腫は症例数が少なく、その有効性を臨床試験で検討することは極めて困難である。本研究では鶏卵漿尿膜(CAM)上に患者由来腫瘍を移植したCAMモデルを多数作成し、同一患者の分身として多種の化学療法を一度に比較する(CAMアバター試験)。

  2. 胆管癌におけるRNA-seq解析に基づく分子サブタイプの解明と臨床的有用性の検討

    研究課題/研究課題番号:24K11928  2024年4月 - 2027年3月

    科学研究費助成事業  基盤研究(C)

    尾上 俊介, 江畑 智希, 國料 俊男, 山口 淳平, 砂川 真輝, 水野 隆史, 馬場 泰輔

      詳細を見る

    担当区分:研究分担者 

    IPNBや乳頭型胆管癌は、通常型胆管癌と異なる予後良好な臨床病理像を持つが、病理学的なアプローチでは明確に分類することは困難だった。我々はトランスクリプトームに基づくアプローチでこれらのサブタイプを分子学的に定義することを目指し、本研究を立案した。
    本研究では切除された胆管癌組織からRNAを抽出し、RNA-seq解析を行う。得られたデータから教師なし分類に基づいた胆管癌の新規分子サブタイプを確立する。分子サブタイプと患者予後及び臨床病理学的所見の相関を明らかにすることで、IPNBおよび乳頭型胆管癌を含む予後の良い一部の胆管癌患者の層別化が可能となり、胆管癌治療における周術期補助療法の差別化が期待される。

  3. 膵癌分子サブタイプの可塑性の解明とその作用機序に基づく新規診断治療法の開発

    研究課題/研究課題番号:22K20819  2022年8月 - 2024年3月

    文部科学省  科学研究費助成事業  研究活動スタート支援

    馬場 泰輔

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2860000円 ( 直接経費:2200000円 、 間接経費:660000円 )

    申請者は、ヒト患者腫瘍移植モデル(以下、PDX)とPDXから樹立した細胞株に対するトランスクリプトーム(RNA-seq)解析の対比を行い、膵癌細胞が増殖環境に応じて膵癌分子サブタイプを柔軟に切り替えていることを明らかにした。本研究では、腫瘍・細胞株のRNA-seqで得られた発現変動遺伝子 (DEG) から、この切り替えを誘導する遺伝子を特定する。さらにこの遺伝子を過剰発現またはノックダウンすることにより、膵腫瘍の分子サブタイプそのものをコントロールすることで、より治療感受性の高い腫瘍に転化させることを目指し、革新的な治療戦略の開発に向けた基礎的データを得る。
    本研究では、膵癌分子サブタイプの可塑性の制御因子としてTFFs(TFF1/TFF2/TFF3)に着目し、これらの遺伝子のClassical programに与える影響を検証した。一般に膵癌細胞株は2次元培養下でBasal-like subtypeに強力に固定されているため、従来の2次元培養下の実験系ではClassical programに関する検証を行うことが難しい。我々は鶏卵漿尿膜法(CAMモデル)を確立し、短期間で腫瘍形成させることで、これらの遺伝子の機能を解析した。その結果、TFF1は膵癌分子サブタイプの制御因子であることが示唆された。
    膵癌のトランスクリプトーム解析から膵癌はClassicalとBasal-likeの二つの主要な分子サブタイプに分類されることが明らかとなった。一般的にClassicalサブタイプは予後がよく化学療法感受性良好、一方のBasal-likeは増殖・転移傾向があり、化学療法感受性が悪いことが知られている。Classical/Basal-like programの制御因子が同定されれば、化学療法の効きにくいBasal-likeサブタイプをClassicalサブタイプへと誘導し、化学療法感受性を飛躍的に向上させる新しい治療戦略が実現する。